Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Pfizer's foundation remains solid, based on strong cash flows generated from a basket of diverse drugs. The company's large size ... With the majority of its cash flow derived from a diverse ...

The company is actively ... Additionally, Pfizer’s financial outlook appears promising, particularly with the potential for improved pricing and cash flow for its Paxlovid product.

Pfizer is rated Zacks Rank #2 (Buy). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of ...

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most number of shares in the company ... In the chart below, we zoom in ...